|
Under construction!. Not available for viewing.
This program was captured live at the NACE Emerging Challenges in Primary Care: Update 2007 series and features Dr. Charles Hennekens. Dr. Hennekens is the Sir Richard Doll Research Professor of Biomedical Science Center of Excellence, Florida Atlantic University, Voluntary Professor of Medicine & Epidemiology and Public Health at the University of Miami Miller School of Medicine and Clinical Professor of Preventive Medicine, NOVA Southeastern University.
Learning Objective
The learning objective for this webcast is to explain why the appropriate aggressive management of patients with statins will confer statistically significant and clinically important reductions in myocardial infarction, stroke, and deaths from cardiovascular disease.
Faculty Disclosure
Dr. Hennekens is a principal investigator on two investigator initiated research grants funded to Florida Atlantic University by Bayer. He is a consultant for Actelion, Amgen, AstraZeneca, Bayer, Biovail, BMS, Chattem, Delaco, the FDA, GSK, Keryx, McNeil, Merck, NIH, Novartis, Pfizer, PriMed, Reliant, TAP, United BioSource Corporation, and UpToDate. He is on the speaker's bureau of AstraZeneca, BMS, Reliant, and Pfizer He is a co-inventor on patents held by Brigham and Women’s Hospital on inflammatory markers and cardiovascular disease.
|
